Resources
Clinical data
140,000+
total patients treated
98.2%
sentinel lymph node detection rate
93.4%
nodal malignancy detection per patient
95.5%
nodal detection rate
2.3
average nodes obtained per patient
Meta-analysis which shows how the Magtrace® lymphatic tracer is superior to blue dye alone and comparable to dual tracer.
Mok et al (2019)
This US based multi-centre prospective study finds the Magtrace® lymphatic tracer is non-inferior to the standard technique for SLNB
Alvarado et al (2019)
A safety study showing the Magtrace® lymphatic tracer to be safe with a low risk of complications
Lorek et al (2019)
The largest cohort of the Magtrace® lymphatic tracer-only application for SLNB, providing simpler logistics and operative planning with excellent clinical results
Man et al (2019)
A study showing the combined use of the Magseed® marker and Magtrace® lymphatic tracer for lesion localisation and SLNB
Pohlodek et al (2019)
This study shows that the Magtrace® lymphatic tracer spared DCIS patients the need for unnecessary SLNB by enabling a delayed SLNB technique
Karakatsanis et al (2019)
A study demonstrating accurate lesion localisation and SLN detection with the combined use of the Magseed® marker and Magtrace® lymphatic tracer
Hersi et al (2018)
A study showing that Magtrace® lymphatic tracer is non-inferior to Tc99 and offers both cost and availability benefits to radioisotope
Ghilli et al (2017)
The MONOS study evaluates the use of the Magtrace® lymphatic tracer as the sole tracer used in SLNB
Karakatsanis et al (2017)
Meta-analysis demonstrating how Magtrace® lymphatic tracer is non-inferior to standard Tc99, with or without Blue dye
Teshome et al (2016)
Meta-analysis showing Magtrace® lymphatic tracer is non-inferior to Tc99 and blue dye
Zada et al (2016)
This study shows that the Magtrace® lymphatic tracer is a safe and effective alternative to the standard technique
Karakatsanis eta al (2016)
This study shows that the Magtrace® lymphatic tracer is a valuable alternative to radioisotope and blue dye
Piñero-Madrona et al (2015)
A study showing that Magtrace® lymphatic tracer is non-inferior to radiotracer and is oncologically safe
Rubio et al (2015)
A feasibility study showing the Magtrace® lymphatic tracer as a contrast agent in MRI to provide pre-op imaging localisation of sentinel lymph nodes
Pouw et al (2015)
A study showing the feasibility of the Magtrace® lymphatic tracer for lesion localisation combined with periareolar injection of blue dye for SLNB
Ahmed et al (2015)
A study showing Magnetic SLNB can be performed easily, safely and equivalently well in comparison to radioisotope alone
Thill et all (2014)
This study shows that the Magtrace® lymphatic tracer is a feasible technique for SLNB with detection rates non-inferior to standard technique
Douek et al (2013)
